The promise and challenges of targeting RSK for the treatment of cancer

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.15, Iss.1, 2011-01, pp. : 1-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Paving the way for targeting RSK in cancer

By Romeo Yves Roux Philippe P

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 1, 2011-01 ,pp. : 5-9

Informa Healthcare

Access to resources Recommend Favorite

Targeting RSK2 in human malignancies

By Kang Sumin Chen Jing

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 1, 2011-01 ,pp. : 11-20

Informa Healthcare

Access to resources Recommend Favorite

The promise of mTOR inhibitors in the treatment of colorectal cancer

By Kim Dae-Dong Eng Cathy

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 12, 2012-12 ,pp. : 1775-1788

Informa Healthcare

Access to resources Recommend Favorite

Locked Nucleic Acid Holds Promise in the Treatment of Cancer

Current Pharmaceutical Design, Vol. 14, Iss. 11, 2008-04 ,pp. : 1138-1142

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting fibroblast growth factor receptor in breast cancer: a promise or a pitfall?

By Bedussi Francesca Bottini Alberto Memo Maurizio Fox Stephen B Sigala Sandra Generali Daniele

Expert Opinion on Therapeutic Targets, Vol. 18, Iss. 6, 2014-06 ,pp. : 665-678

Informa Healthcare

Access to resources Recommend Favorite